REYDERMAN; Larisa

Patent Applications and Registrations

Patent applications and USPTO patent grants for REYDERMAN; Larisa.The latest application filed is for "ezh2 inhibitors for treating lymphoma".

Company Profile

4.6.10

REYDERMAN; Larisa - Watchung NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Ezh2 Inhibitors For Treating Lymphoma App 20200323866 - KEILHACK; Heike ; et al.	2020-10-15
Ezh2 Inhibitors For Treating Lymphoma App 20200022987 - KEILHACK; Heike ; et al.	2020-01-23
Ezh2 Inhibitors For Treating Lymphoma App 20190175604 - KEILHACK; Heike ; et al.	2019-06-13
EZH2 inhibitors for treating lymphoma Grant 10,166,238 - Keilhack , et al. J	2019-01-01
Ezh2 Inhibitors For Treating Lymphoma App 20170216300 - KEILHACK; Heike ; et al.	2017-08-03
Pharmaceutical formulations: salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxy-methyl]-8-phenyl-1,7-diaza-s- piro[4.5]decan-2-one and treatment methods using the same Grant 9,345,692 - Qiu , et al. May 24, 2	2016-05-24
Pharmaceutical Formulations: Salts Of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-sp- Iro[4.5]decan-2-one And Treatment Methods Using The Same App 20140088128 - Qiu; Zhihui ; et al.	2014-03-27
Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-sp- iro[4.5]decan-2-one and treatment methods using the same Grant 8,404,702 - Qiu , et al. March 26, 2	2013-03-26
Par-1 Antagonism In Fed Or Antacid-dosed Patients App 20120095052 - Reyderman; Larisa ; et al.	2012-04-19
Pharmacokinetically-based Dosing Regiments Of A Thrombin Receptor Antagonist App 20120028976 - Reyderman; Larisa ; et al.	2012-02-02
Pharmaceutical Formulations:salts Of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-sp- Iro[4.5]decan-2-one And Treatment Methods Using The Same App 20120015921 - Qiu; Zhihui ; et al.	2012-01-19
Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaz- a-spiro[4.5]decan-2-one and treatment methods using the same Grant 7,981,905 - Qiu , et al. July 19, 2	2011-07-19
Pharmaceutical Formulations: Salts Of 8-[-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one And Treatment Methods Using The Same App 20100137348 - Qiu; Zhihui ; et al.	2010-06-03
Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaz- a-spiro[4.5]decan-2-one and treatment methods using the same Grant 7,563,801 - Qiu , et al. July 21, 2	2009-07-21
Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaz- a-spiro[4.5]decan-2-one and treatment methods using the same App 20070275051 - Qiu; Zhihui ; et al.	2007-11-29

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.